AUCKLAND, NZ – Medtrade exhibitor Fisher & Paykel Healthcare Corp revealed positive results for the full year ended March 31, 2025. “During the 2025 financial year, we stayed focused on the fundamentals of our business and achieved strong results,” said Lewis Gradon, managing director and CEO via press release, “with annual revenue of more than $2 billion for the first time in our history.”
Total operating revenue was a record $2.02 billion, an increase of 16% from the prior financial year, or 14% in constant currency. This was driven by broad-based growth in hospital consumables and double-digit growth in masks for treating obstructive sleep apnea.
Net profit after tax for the financial year was $377.2 million, a 43% increase over the 2024 financial year, or 30% in constant currency. These growth rates are against underlying net profit after tax for the 2024 financial year, which excluded three abnormal items.
For the Hospital product group, which includes products used in respiratory, acute and surgical care, revenue for the full year was $1.28 billion, up 18% from the previous financial year, or 16% in constant currency. Sales of new applications consumables were up 20% over the prior financial year, or 18% in constant currency.
For the Homecare product group, which includes products used in the treatment of obstructive sleep apnea (OSA) and respiratory support in the home, revenue for the full year was $739.9 million, up 13% over the previous financial year, or 11% in constant currency. OSA masks revenue was up 14% for the full year, or 11% in constant currency.
During the 2025 financial year, Fisher & Paykel Healthcare invested $226.9 million into research and development. The company expanded the roll-out of its F&P Airvo™ 3 device and F&P 950™ System in the United States and increased the adoption of its products for use in anaesthesia, F&P Optiflow Switch™ and F&P Optiflow Trace™. The business also launched two new masks for treating OSA, the F&P Nova™ Micro mask in April 2024 and the F&P Nova Nasal mask in March 2025.
